Tiny Implant Could Help Cats with Weight Loss, Experts Say It's a Game Changer
A tiny implant under the skin of cats is being tested in a clinical trial as a potential weight loss solution for feline friends. The device, called OKV-119, releases a GLP-1 medication that mimics the physiological effects of fasting, leading to improved insulin sensitivity, reduced fat mass, and more efficient energy metabolism.
According to experts, roughly six in 10 cats in the US are carrying too much weight, which can lead to serious health issues like diabetes. "In veterinary medicine for the last 100 years, the only prescription we had was feed less, exercise more, and that just doesn't work for all types of obesity," said Dr. Ernie Ward, a top pet obesity expert.
The benefits of this treatment go beyond weight loss, with improvements in diabetes risk and long-term health seen in human data. The trial aims to enhance cats' quality of life and promote healthy aging, which is especially important as many cats live up to 20 years or more.
While the results are promising, there are still unknowns surrounding the efficacy, side effects, and cost of the treatment. Okava Pharmaceuticals, the company behind the MEOW-1 trial, estimates that the drug will cost around $100 per month.
One cat owner, Savannah Tielking, is eager to see the treatment work for her 10-year-old cat Runkle, who has gained weight and spends most of his days sleeping. "He's a lounger... big lounger," she said. "I think that if my vet came to me and was like, 'He's diabetic. We've tried everything else. We should consider that' โ then most definitely."
The MEOW-1 trial is expected to conclude next summer, with the company seeking FDA approval for cat use in the next two years. With dogs not far behind, this tiny implant could revolutionize the way we treat our furry friends and improve their quality of life.
A tiny implant under the skin of cats is being tested in a clinical trial as a potential weight loss solution for feline friends. The device, called OKV-119, releases a GLP-1 medication that mimics the physiological effects of fasting, leading to improved insulin sensitivity, reduced fat mass, and more efficient energy metabolism.
According to experts, roughly six in 10 cats in the US are carrying too much weight, which can lead to serious health issues like diabetes. "In veterinary medicine for the last 100 years, the only prescription we had was feed less, exercise more, and that just doesn't work for all types of obesity," said Dr. Ernie Ward, a top pet obesity expert.
The benefits of this treatment go beyond weight loss, with improvements in diabetes risk and long-term health seen in human data. The trial aims to enhance cats' quality of life and promote healthy aging, which is especially important as many cats live up to 20 years or more.
While the results are promising, there are still unknowns surrounding the efficacy, side effects, and cost of the treatment. Okava Pharmaceuticals, the company behind the MEOW-1 trial, estimates that the drug will cost around $100 per month.
One cat owner, Savannah Tielking, is eager to see the treatment work for her 10-year-old cat Runkle, who has gained weight and spends most of his days sleeping. "He's a lounger... big lounger," she said. "I think that if my vet came to me and was like, 'He's diabetic. We've tried everything else. We should consider that' โ then most definitely."
The MEOW-1 trial is expected to conclude next summer, with the company seeking FDA approval for cat use in the next two years. With dogs not far behind, this tiny implant could revolutionize the way we treat our furry friends and improve their quality of life.